Text Size
72 studies found for:    "Familial hypercholesterolemia"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
21 Recruiting Atorvastatin Three Year Pediatric Study
Condition: Familial Hypercholesterolemia
Intervention: Drug: atorvastatin
22 Completed
Has Results 		PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin
Condition: Familial Hypercholesterolemia
Interventions: Drug: Rosuvastatin;   Drug: Placebo
23 Completed
Has Results 		Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease
Conditions: Heterozygous Familial Hypercholesterolemia;   Coronary Artery Disease
Interventions: Drug: mipomersen sodium;   Drug: placebo
24 Unknown † Soy Food Intervention Trial
Condition: Familial Hypercholesterolemia
Interventions: Dietary Supplement: soy protein diet;   Dietary Supplement: rapeseed oil
25 Recruiting Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
Condition: Homozygous Familial Hypercholesterolemia or PCSK9 Mutations
Intervention: Drug: AMG 145
26 Unknown † Effect of Rapeseed Oil and Sunflower Oil
Condition: Familial Hypercholesterolemia
Interventions: Dietary Supplement: rapeseed oil;   Dietary Supplement: sunflower oil
27 Not yet recruiting Effect of Omega-3 Fatty Acid on Endothelial Function
Condition: Familial Hypercholesterolemia
Interventions: Drug: Omega-3;   Drug: placebo
28 Terminated Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.
Conditions: Atherosclerosis;   Heterozygous Familial Hypercholesterolemia
Intervention: Drug: Pactimibe sulfate
29 Terminated Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care
Condition: Heterozygous Familial Hypercholesterolaemia
Interventions: Drug: Placebo;   Drug: Eprotirome
30 Completed Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia
Condition: Type II Hyperlipidaemia
Interventions: Drug: Placebo;   Drug: JTT-705 300mg;   Drug: JTT-705 600mg;   Drug: JTT-705 900mg
31 Completed Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia
Condition: Type II Hyperlipidemia
Interventions: Drug: JTT-705 600 mg and pravastatin 40 mg;   Drug: JTT-705 300 mg and pravastatin 40 mg;   Drug: Placebo and pravastatin 40 mg
32 Completed Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Conditions: Hypertension;   Angina Pectoris;   Hypercholesterolemia;   Familial Hypercholesterolemia
Intervention: Drug: Amlodipine/Atorvastatin
33 Completed Effects of Low-density Lipoprotein (LDL) Apheresis on Inflammatory and Lipid Markers
Condition: Familial Hypercholesterolemia
Intervention: Procedure: LDL Apheresis
34 Completed A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels
Condition: Type II Hyperlipidemia
Intervention: Drug: DRL-17822 or placebo
35 Completed
Has Results 		Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: mipomersen sodium
36 Active, not recruiting An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
Conditions: Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
Intervention: Drug: mipomersen sodium
37 Not yet recruiting Cardiovascular Disease in FH Heterozygous
Condition: Familial Hypercholesterolemia
Intervention:
38 Completed A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)(COMPLETED)
Conditions: Hypercholesterolemia;   Familial Hypercholesterolemia;   Homozygous Sitosterolemia
Interventions: Drug: Ezetimibe;   Drug: Ezetimibe + other lipid-lowering medication(s)
39 Completed Low-Density Lipoprotein (LDL) Apheresis Using H.E.L.P. Therapy
Condition: Familial Hypercholesterolemia
Intervention: Device: HELP Secura (apheresis treatment)
40 Completed A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)(COMPLETED)
Conditions: Hypercholesterolemia;   Familial Hypercholesterolemia;   Homozygous Sitosterolemia
Interventions: Drug: Ezetimibe;   Drug: Ezetimibe + other lipid-lowering medication(s)
To Top

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
† Indicates status has not been verified in more than two years